Spots Global Cancer Trial Database for Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Official Title: A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Study ID: NCT05237713
Interventions
Study Description
Brief Summary: Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.
Detailed Description: To study the erythroid response rate (HI-E) of canakinumab in patients with IPSS-R very low, low, or intermediate risk MDS or MDS/MPN after 6 months of treatment.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Medizinisches Versorgungszentrum "Onkologischer Schwerpunkt am Oskar- Helene-Heim", Berlin, , Germany
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Medizinischen Klinik und Poliklinik I / Hämatologie, Dresden, , Germany
Klinik und Poliklinik für Hämatologie und Zelltherapie, Hämostaseologie, Leipzig, , Germany
Contact Details
Name: Anne Sophie Kubasch, Dr.
Affiliation: University Leipzig
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
